Phase II Safety Study of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as Second-line Therapy in Patients With Hepatocellular Carcinoma

被引：7

作者：

Bolondi, L. ^{[1
]}

Tak, W. Y. ^{[2
]}

Gasbarrini, A. ^{[3
]}

Santoro, A. ^{[4
]}

Colombo, M. ^{[5
]}

Lim, H. Y. ^{[6
]}

Mazzaferro, V. ^{[7
,10
]}

Wiest, R. ^{[8
]}

Reig, M. ^{[9
]}

Bruix, J. ^{[9
]}

机构：

[1] St Orsola Marcello Malpighi Hosp, Dept Internal Med & Gastroenterol, Bologna, Italy

[2] Kyungpook Natl Univ Hosp, Dept Internal Med, Taegu, South Korea

[3] Policlin Univ Agostino Gemelli, Rome, Italy

[4] Humanitas Canc Ctr, Dept Med Oncol & Hematol, Rozzano, Italy

[5] Policlin Univ, Osped Maggiore, Div Hepatol, Milan, Italy

[6] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea

[7] Natl Canc Inst, Dept Surg, I-20133 Milan, Italy

[8] Univ Hosp Regensburg, Dept Internal Med 1, Regensburg, Germany

[9] Univ Barcelona, BCLC Grp, Liver Unit, Hosp Clin, Barcelona, Spain

[10] Natl Canc Inst, Expt Oncol Hepatooncol Grp, I-20133 Milan, Italy

来源：

关键词：

D O I：

10.1016/S0959-8049(11)71887-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：S464 / S464

页数：1